Mental health challenges will be the greatest impact of the pandemic. Anxiety Disorders, PTSD, Childhood learning loss, are just a few of the mental health consequences of prolonged isolation and prolonged fear. This presentation will help you distinguish human suffering as a result of a global pandemic vs. psychopathology which mandates both behavioral and pharmacological interventions.

What do primary care providers need to know about SSRI and dementia? Join expert faculty as they review important questions they get asked about these topics!

What do primary care providers need to know about depression and ADHD? Join expert faculty as they review important questions they get asked about these topics!

Individuals with major depressive disorder (MDD) experiencing an incomplete response to initial antidepressant monotherapy can suffer functional impairment and poor clinical outcomes. The interactive, branching activity provides you with an opportunity to assess such a patient and make management decisions over multiple visits in a primary care setting. By the end of this complex case, you will be better equipped to recognize when a patient would benefit from treatment advancement and will understand the patient and pharmacologic factors involved in individualizing treatment escalation, including how and when to employ combination antidepressant therapy or augmentation with a second-generation antipsychotic agent.

This video-based resource activity will feature a dialogue between two expert faculty on the health, psychosocial, and functional burden of MDD on patients who experience an incomplete response to treatment. The discussion will emphasize the importance of prompt recognition of these individuals so that therapy advancement can occur at the earliest opportunity and will provide practical tools to help PCPs make this identification.

In this video-based resource activity, expert faculty will discuss options for advancing antidepressant therapy in patients with an incomplete response to antidepressant monotherapy, including the neurochemical rationale for combining antidepressant therapy. It will also provide an approach for selecting antidepressant therapy in which the drugs’ clinical profiles correspond best to individual patient’s symptoms and other clinical factors.

This video-based resource activity is designed to provide an overview of adjunctive therapy to treat patients with MDD who are experiencing a partial treatment response. These therapies include second-generation antipsychotic agents, esketamine, and non-pharmacologic modalities. Expert faculty will discuss the neurochemical rationale behind adjunctive treatment and differentiate between the various pharmacologic agents, with an emphasis on efficacy, adverse effects, and clinical profiles that can guide their use.

Join us as we discuss data from the National Longitudinal Study of Adolescent to Adult Health examining how family relationships impact depression.